tumor mutational burden (TMB)

Keytruda

Pharma

Merck's Keytruda inches toward another biomarker-based approval

Merck’s immuno-oncology competitors have tried to win approvals using a new biomarker, so far fruitlessly. It looks like Merck itself might succeed.

Carly Helfand Apr 7, 2020 11:08am

Keytruda

Merck analyses throw doubt on new biomarker's utility

Sep 8, 2019 3:45am

Imfinzi

AstraZeneca's I-O duo flops another late-stage lung cancer trial

Aug 21, 2019 10:54am